Abstract
Physicians and insurance companies use clinical practice guidelines (CPGs) to make decisions about patient care.1 These guidelines include recommendations derived from a systematic review of research evidence and careful consideration of benefits and harms associated with medical interventions. Ideally, guidelines should be free from biased recommendations and should consider patients’ best interests; however, panels often include physicians with financial ties to pharmaceutical or medical device industries.1 Evidence suggests that physicians receiving industry payments are likely to assess clinical trials more favorably.2 Small payments, such as gifts or meals provided by industry, may even increase the likelihood that physicians will prescribe brand-name drugs.3,4 For these reasons, the Institute of Medicine’s Committee on Conflicts of Interest in Medical Research, Education, and Practice states, “conflicts of interest threaten the integrity of scientific investigations, the objectivity of professional education, the quality of patient care, and the public’s trust in medicine.”5